News & Events
< Back to News Overview
Sunshine Heart CEO presents at 9th Annual C21 BioVentures Conference
28 / 05 / 2007
Sunshine Heart, Inc. (ASX: SHC) announced today that Chief Executive Officer Don Rohrbaugh was among the presenters at the C21 BioVentures' 9th annual meeting, held in Monterey, California, USA. Sunshine Heart is a global medical device company that is developing the C-PulseT, an innovative, implantable mechanical heart assist device to treat heart failure.
John Brennan, Partner of CM Capital, Brisbane, a SHC investor, also attended the conference. John indicated that "Sunshine Heart, Inc. was one of more than 50 companies highlighted at the C21 Bioventures meeting, which was attended by more than 300 individuals representing pharmaceutical and venture capital organizations. Sunshine Heart's presentation, which outlined the unique product and market advantages of the Company's C-PulseT heart assist device, was well received by the attendees". Many of the life science companies that have presented at C21 in the past have subsequently become highly successful biotech-pharma ventures.
"It was a pleasure to present Sunshine Heart's C-PulseT technology to such an esteemed audience," said Mr Rohrbaugh, who noted that "C21's advisory board includes 42 key financial decision makers from leading Silicon Valley venture capital, banking, and financial organizations". Mr Rohrbaugh reported that SHC recently completed development of the Company's second-generation C-PulseT System, and is preparing to begin U.S. feasibility clinical trials later this year.
John Brennan, Partner of CM Capital, Brisbane, a SHC investor, also attended the conference. John indicated that "Sunshine Heart, Inc. was one of more than 50 companies highlighted at the C21 Bioventures meeting, which was attended by more than 300 individuals representing pharmaceutical and venture capital organizations. Sunshine Heart's presentation, which outlined the unique product and market advantages of the Company's C-PulseT heart assist device, was well received by the attendees". Many of the life science companies that have presented at C21 in the past have subsequently become highly successful biotech-pharma ventures.
"It was a pleasure to present Sunshine Heart's C-PulseT technology to such an esteemed audience," said Mr Rohrbaugh, who noted that "C21's advisory board includes 42 key financial decision makers from leading Silicon Valley venture capital, banking, and financial organizations". Mr Rohrbaugh reported that SHC recently completed development of the Company's second-generation C-PulseT System, and is preparing to begin U.S. feasibility clinical trials later this year.